BioSenic

BioSenic faces cash crunch, eyes phase 3 | Pharmtales

BioSenic seeks to survive cash crunch and enter phase 3 for GvHD drug

Anika Sharma

BioSenic, the Belgian biotech born from the merger of Bone Therapeutics and Medsenic last year, is devising a survival plan ...